Vanqua Bio to Present Pre-Clinical Data on VQ-201, a Next Generation C5aR1 Antagonist for the Treatment of Inflammatory Disorders - Vanqua Bio CHICAGO, Dec. 05, 2024 (GLOBE NEWSWIRE) — Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present at the 8th Annual Complement-Based Drug Development Summit, wh...

www.vanquabio.com/vanqua-bio-t...
Looking for this #C5aR1 data. If you attended, could you please share ?
#VanquaBio #InflaRx $IFRX #Biogen $BIIB

⏱️ Live Feed: Dr. Monica Olcina (University of Oxford, UK) discussed how targeting the #complement receptor #C5aR1 could enhance #radiotherapy efficacy in #immunosuppressive tumor #microenvironments.